H eart failure (HF) with preserved ejection fraction (HFpEF) is common, and patients with HFpEF have similar poor outcomes as those with HF with reduced ejection fraction (EF). 1, 2 The American College of Cardiology/American Heart Association/Heart Failure Society of America guideline for HF recommends that systolic blood pressure (SBP) should be controlled in patients with HFpEF, 3 and i ts2017upda te 4 makes a new recommendation for an optimal SBP target level of less than 130 mm Hg for patients with HFpEF and persistent hypertension. However, an optimal SBP target level is less clear for patients with HFpEF. Hypertension is a major risk factor for incident HF, and treatment of hypertension, particularly to an SBP target level of less than 120 mm Hg, has been demonstrated to substantially lower the risk of incident HF. [5] [6] [7] [8] However, once patients develop HF, a lower SBP level may have a paradoxical association with a higher risk of cardiovascular morbidity and mortality. [9] [10] [11] Less is known about this association in patients with HFpEF, the examination of which is the objective of this study.
Methods

Data Source and Study Population
The current analyses are based on data from the Medicarelinked Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF) registry, the details of which have been published before.
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Briefly, medical records of 48 612 HF hospitalizations from 259 hospitals in 48 states were abstracted using a web-based information system. These patients were hospitalized between March 1, 2003, and December 31, 2004 , and had an International Classification of Diseases, Ninth Revision, Clinical Modification code for HF as a principal discharge diagnosis. Data on demographics characteristics, medical history, symptoms, signs, admission and discharge medications, inpatient procedures, and short-term outcomes were collected. 12, 15 Longterm outcomes data were obtained by linking data from the OPTIMIZE-HF registry to the Medicare data up to December 31, 2008, using a probabilistic linking approach, which identified 26 376 unique patients. A total of 25 354 were discharged alive, 13,15 of whom 8873 (35.0%) had HFpEF defined as EF of 50% or greater. 3 The original OPTIMIZE-HF protocol was approved by the local or central institutional review boards. The current study is based on a deidentified copy of the Medicare-linked OPTIMZE-HF data approved by the Centers for Medicare and Medicaid Services and by the local institutional review board and Research and Development Committee. Written informed consent was not required owing to the retrospective nature of the study.
Assembly of a Cohort With Stable SBP
Data on SBP levels were collected from patients in the supine position from times closest to admission and discharge, and automated electronic data checks were used to prevent outlying SBP values. 9 We excluded 85 patients who had SBP levels greater than 300 mm Hg or less than 60 mm Hg. We restricted our analysis to 3915 patients (44.1%) with stable inpatient SBP levels, defined as an admission to discharge variation of 20 mm Hg or less (median, -4; range, -20 to 20) . Of the 3915 patients with stable SBP levels, 1076 patients (27.5%) had a discharge SBP level of less than 120 mm Hg (eFigure 1 in the Supplement). We chose the SBP cutoff of 120 because SBP level less than 120 mm Hg has been shown to be associated with poor outcomes in HF.
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Of the 4873 patients (54.9%) with a variable inpatient SBP level (admission to discharge variation >20 mm Hg), 4077 patients (83.7%) had a mean (median; range) decrease of -47 mm Hg (-41 mm Hg; -178 to -21 mm Hg), and 796 patients (14.5%) had a mean (median; range) increase of 35 mm Hg (32 mm Hg; 21 to 102 mm Hg). We chose to restrict our primary analysis to patients with stable inpatient SBP levels to minimize bias due to measurement errors and acute inpatient events affecting SBP. This also allowed us to avoid potential exposure misclassification. For example, a patient with a high admission SBP level (eg, 180 mm Hg) and an inhospital decrease of 80 mm Hg would be misclassified in the lower (<120 mm Hg) discharge SBP group.
Assembly of a Balanced Cohort
To attenuate bias due to imbalances in baseline characteristics and to enhance our ability to draw inferences about association, we used propensity score matching to assemble a cohort in which patients with SBP levels less than 120 mm Hg vs 120 mm Hg or greater would be expected to be balanced on all measured baseline characteristics. [16] [17] [18] [19] We estimated propensity scores for discharge SBP level less than 120 mm Hg for each of the 3915 patients with a stable SBP using a nonparsimonious multivariable logistic regression model, in which SBP level less than 120 mm Hg was used as the dependent variable and the 58 baseline variables were used as covariates (eFigure 2 in the Supplement). We included diastolic blood pressure (DBP) in the model to attenuate any independent association of DBP level with outcomes. However, we also repeated the model after excluding DBP. The propensity score for SBP level less than 120 mm Hg for a patient is that patient's probability of having an SBP
Key Points
Question How is systolic blood pressure associated with outcomes in patients with heart failure with preserved ejection fraction?
Findings In a propensity score-matched observational study of hospitalized patients with HF and ejection fraction 50% or greater in the national Medicare-linked OPTIMIZE-HF registry, a discharge systolic blood pressure level of less than 120 mm Hg was associated with a significantly higher risk of 30-day, 1-year, and long-term all-cause mortality.
Meaning
A systolic blood pressure level of less than 120 mm Hg identifies patients with heart failure with preserved ejection fraction at higher risk for short-and long-term mortality and emphasizes the need for future prospective studies to evaluate optimal systolic blood pressure treatment goals in this patient population.
level less than 120 mm Hg given the 58 baseline characteristics used in the propensity score model (57 for the model without DBP). We then used a matching algorithm, described previously, 20 
Assembly of Sensitivity Cohorts
To ensure that the findings of our primary cohort were not sensitive to methodological approaches described earlier, we assembled 4 separate sensitivity cohorts. 
Outcomes Data
Our primary outcomes included all-cause mortality and HF readmission at 30 days, 1 year, and during overall median follow-up of 2.1 (overall 6) years up to December 31, 2008. Secondary outcomes included all-cause readmission and the 2 combined end points of all-cause readmission or all-cause mortality and HF readmission or all-cause mortality. All outcomes data were collected from Medicare 100% MedPAR File and 100% Beneficiary Summary File.
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Statistical Analyses
Between-group baseline characteristics were compared using Pearson χ 2 and Wilcoxon rank-sum tests, as appropriate. All outcome analyses were conducted using matched data. KaplanMeier survival analysis was used to compare cumulative risk of all-cause mortality by discharge SBP level less than 120 vs 120 mm Hg or greater, censoring patients at readmission or study end, whichever came first. Cox proportional hazards models were used to estimate hazard ratios (HRs) and 95% confidence intervals for outcomes associated with SBP level less than 120 mm Hg using SBP level of 120 mm Hg or greater as reference. For the readmission model, patients were censored at death or study end, whichever came first. To assess for nonlinearity, we fitted restricted cubic spline models with 4 knots at SBP levels of 110 mm Hg, 120 mm Hg (reference), 140 mm Hg, and 150 mm Hg using both matched data and prematched data, adjusting for propensity scores. Formal sensitivity analyses were conducted to quantify the degree of hidden bias that could potentially explain any significant associations. Subgroup analyses were conducted to assess homogeneity of the association between discharge SBP less than 120 mm Hg and overall all-cause mortality in clinically relevant subgroups of patients in the primary matched cohort. All statistical analyses were conducted using SPSS statistical software version 24 (IBM SPSS) and SAS statistical software version 9.4 (SAS Institute Inc).
Results
Baseline Characteristics
The 1802 matched patients had a mean (SD) age of 79 (10) years and a mean (SD) EF of 59% (7%). A total of 1147 (63.7%) were women and 134 (7.4%) were African American. The mean (median; range) SBP level was 121 (120; 75-193) mm Hg, with only 13 matched patients having an SBP level less than 90 mm Hg (2 had <80 mm Hg). Before matching, patients with a discharge SBP level less than 120 mm Hg had a lower prevalence of hypertension and diabetes and a higher prevalence of atrial fibrillation, and fewer of these patients were taking angiotensin converting enzyme (ACE) inhibitors and β-blockers ( Table 1) . These and other measured baseline characteristics were balanced after matching; the absolute standardized differences for all 58 baseline characteristics were less than 10% (Table 1 ; eFigure 2 in the Supplement).
Outcomes in Patients With HF, EF 50% or Greater, and Stable SBP
Thirty-day all-cause mortality occurred in 91 (10%) and 45 (5%) of matched patients (n = 1802) with a discharge SBP level less than 120 vs 120 mm Hg or greater, respectively (HR, 2.07; 95% CI, 1.45-2.95; P < .001) ( Table 2 ). The association between an SBP level less than 120 mm Hg and higher risk of all-cause mortality persisted both at 1 year (39% vs 31%; HR, 1.36; 95% CI, 1.16-1.59; P < .001) ( Table 2 ) and 6 years (75% vs 71%; HR, 1.17; Left ventricular ejection fraction 59 (7) 59 (7) .66 59 (7) 59 (7) .82
Medical history
No known prior heart failure 121 (11) Figure 1 ). Findings from our restricted cubic spline analysis demonstrate that there was no evidence of a nonlinear association between SBP and allcause mortality (P >.20) (Figure 2 ). Findings from our subgroup analyses demonstrate that the association between SBP levels less than 120 mm Hg and overall all-cause mortality in our matched cohort was homogenous across various clinically relevant subgroups of patients, except those with a glomerular filtration rate less than 45 mL/min/1.73 m 2 and those who received a discharge prescription for ACE inhibitors ( Figure 3) . Of the 901 matched pairs, 125 pairs (13.9%) clearly had a shorter 30-day survival rate than their matched counterparts, and 85 of 125 pairs (68%) of those patients belonged to the lower SBP group (sign score test P < .001). A hidden covariate that is a near-perfect probability of 30-day all-cause mortality and not strongly associated with any of the 58 variables used in our propensity score model could potentially explain this association if it would also increase the odds of having an SBP level less than 120 mm Hg by about 56%. Patients with SBP levels less than 120 mm Hg also had shorter 1-year and overall survival than their matched counterparts, and these associations were also rather insensitive (sign score test P < .001) to bias by a hidden confounder. Associations of SBP level less than 120 mm Hg with other outcomes are displayed in Table 2 .
When we excluded DBP from the logistic regression model for propensity score, we were able to assemble a matched balanced cohort of 2104 patients who had a mean (SD) age of 79 (11) years and a mean (SD) EF of 59% (7%); 1321 (62.8%) were women, and 160 (7.6%) were African American. Matched patients in the 2 SBP groups were balanced on all 57 baseline characteristics. Mean (SD) for DBP patients in the SBP level less than 120 vs 120 mm Hg or greater groups were 60 and 69 mm Hg, respectively, which is similar to the prematch DBP level values ( 
Outcomes in Patients With HF and EF 50% or Greater, Regardless of SBP Stability
The 4582 matched patients with an EF of 50% or greater regardless of SBP stability had a mean (SD) age of 79 (10) years and a mean (SD) EF of 59% (7%), and 3074 (67.1%) were women and 410 (8.9%) were African American. These patients were balanced on all 58 baseline characteristics. All-cause mortality over 6 years of follow-up occurred in 1637 (72%) and 1595 (69.6%) of patients with a discharge SBP level less than 120 vs 120 mm Hg or greater, respectively (HR, 1.09; 95% CI, 1.02-1.17; P = .01) (eTable in the Supplement). Associations with other outcomes are displayed in the eTable in the Supplement.
Association With Admission SBP Less Than 120 mm Hg
The 2958 matched patients with an EF of 50% or greater had a mean (SD) age of 79 (10) years, a mean (SD) EF of 59% (7%) and 1850 (62.5%) were women and 203 (6.9%) were African American. These patients were balanced on all 58 baseline characteristics. Six-year all-cause mortality occurred in 1128 (76.3%) and 1041 (70.4%) of patients with an admission SBP level less than 120 vs 120 mm Hg or greater, respectively (HR, 1.28; 95% CI, 1.18-1.40; P < .001). Associations with other outcomes are displayed in eTable in the Supplement.
Association With Discharge SBP Less Than 130 mm Hg
The 2228 matched patients had a mean (SD) age of 79 (10) 
Discussion
Findings from the current study demonstrate that among hospitalized patients with HFpEF, a discharge SBP level of less than 120 mm Hg was associated with a significantly higher risk of 30-day, 1-year, and overall all-cause mortality and that this association was essentially unchanged when lower SBP was defined as SBP levels less than 130 mm Hg. An SBP level less than 120 mm Hg was also associated with a significantly higher risk of the combined end points of HF readmission or mortality at all 3 times. These findings, taken together with those from multiple sensitivity cohorts, provide evidence of a consistent association between a lower SBP level and poor outcomes in patients with HFpEF. Higher mortality associated with a lower SBP level in patients with HFpEF may reflect differences in cause, pathophysiology, and stage of disease. Hypertension often precedes the development of clinical HF and is the most common cause of morbidity in patients with HF. 5, 6, 24 However, fewer (prematched) patients in the SBP level less than 120 mm Hg group in our study (Table 1 ) had a history of hypertension, suggesting that HFpEF in these patients may not have been associated with hypertension. A lower SBP level in patients with HFpEF may be due to SBP-lowering drugs; however, fewer patients in the lower SBP group were receiving these drugs. It is possible that a lower SBP level in HFpEF may also reflect a more advanced disease state and lower cardiac output. A higher pulse pressure has been shown to be associated with a higher risk of death in HFpEF (EF ≥ 50%). 25 However, that is unlikely to explain our findings because patients in the higher SBP group had a lower mortality despite a higher pulse pressure. A higher proportion of prematched patients with a lower SBP level were receiving loop diuretics, which may have contributed to the lower SBP level, greater reflex neurohormonal activation, and poor outcomes. 16 While our propensity score matching achieved substantial between-group balance in all measured confounders, imbalances in their severity may remain and persist during follow-up. Furthermore, imbalances in unmeasured confounders may also in part explain the observed poor outcomes in the lower SBP group. Nearly half of the matched patients with lower SBP levels were receiving ACE inhibitors and β-blockers, which could have further lowered SBP levels during follow-up. Hypotension has been shown to be associated with sudden cardiac death. 26-28 Thus, a higher incidence of sudden cardiac death in the lower SBP group may also in part explain the lack of association with readmission in that group. The association between SBP level less than 120 mm Hg and HF readmission was modest and variable. If a higher proportion of patients in the lower SBP group had more advanced HF, then pump failure could in part explain the higher HF readmission in that group. 29 However, lack of consistency of this association across various cohorts and timeframes suggest this association may not be intrinsic in nature. For example, among patients with stable SBP levels, a discharge SBP level less than 120 mm Hg had a significant association with 30-day HF readmission but not with 1-year and overall HF readmissions. In contrast, among those with variable SBP levels, a discharge SBP level less than 120 mm Hg had a significant association with HF readmission overall but not during shorter follow-up. Finally, an admission SBP level less than 120 mm Hg had a significant association with all outcomes but not with HF readmission. Several prior studies have examined the association of a lower SBP level with outcomes in hospitalized older adults with HF. 9, [30] [31] [32] [33] Most of these studies were small, and only 1 was dedicated to HFpEF. 33 In contrast, our study is distinguished by a larger sample size, the use of a cohort with stable admission to discharge SBP, the use of an EF cutoff of 50% or greater to define HFpEF, the use of propensity score matching to assemble a balanced cohort, the use of subgroup analyses to demonstrate homogeneity, the use of multiple sensitivity analyses, and the use of formal sensitivity analyses to assess bias by a potential unmeasured confounder. National guidelines for HF and hypertension recommend that SBP levels should be controlled in patients with HFpEF in general and to less than 130 mm Hg in patients with HF and persistent hypertension. 22, 23 These recommendations are extrapolated from populations without HF because direct evidence from patients with HFpEF is limited. The ACE inhibitors and angiotensin II receptor blockers have been shown to modestly lower SBP levels in patients with HFpEF, but this did not translate into better outcomes. 34, 35 Findings from observational studies suggest that a lower SBP level may be associated with poor outcomes in patients with HF. [9] [10] [11] This poorly understood phenomenon of reverse epidemiology is not unique to SBP and has also been described for other traditional HF risk factors. [36] [37] [38] Findings from the current study provide evidence that a lower SBP level is a marker of underlying pathophysiologic processes that is associated with poor outcomes in patients with HFpEF, an observation that may help design future trials testing new therapies in HFpEF. 39 Future prospective randomized clinical trials also need to examine the effect of various SBP target levels on outcomes in patients with HFpEF. Hazard ratios and 95% confidence intervals for all-cause mortality by discharge systolic blood pressure level in 3915 patients with heart failure with preserved ejection fraction of 50% or greater according to restricted cubic spline regression models using 4 knots at blood pressures of 110 mm Hg, 120 mm Hg (reference), 140 mm Hg, and 150 mm Hg. Solid black lines indicate hazard ratios, and shaded areas indicate 95% CI. Plots on the left panel (A) are based on 3906 prematch patients (9 prematch patients had systolic blood pressure levels >200 mm Hg and were excluded), adjusting for propensity scores, and those on the right panel (B) are based on 1802 matched patients (none had systolic blood pressure levels >200 mm Hg) balanced on 58 baseline characteristics. Spline curves were truncated at a systolic blood pressure level of 200mmHg.
Limitations
There are several limitations to our study. Because of the observational nature of our study, bias due to unmeasured confounders is possible. Findings from our sensitivity analyses suggest that the harmful association of SBP level less than 120 mm Hg and all-cause mortality is rather insensitive to a hidden bias. We had no data on postdischarge SBP level, and SBP crossover during follow-up may result in regression dilution and potential underestimation of the true association.
40 Our database on hospitalized patients with HFpEF may not be generalizable to ambulatory patients with HFpEF because determinants of blood pressure as well as measurement of blood pressure in these 2 settings are different.
Conclusions
In hospitalized older patients with HFpEF, an SBP level less than 120 mm Hg is independently associated with a higher risk of all-cause mortality and the combined end points of readmissions or mortality. Future studies need to prospectively evaluate optimal SBP treatment goals in patients with HFpEF. 
